Two very different contenders are nearing FDA decisions: CagriSema, an injectable combo aiming for deeper weight loss, and orforglipron, a once-daily pill. A neutral look at where each stands and what the data shows.
Two notable GLP-1 candidates are nearing FDA decisions. CagriSema, an injectable combination of cagrilintide and semaglutide, produced about 20.4 percent average weight loss at 68 weeks in a phase 3 trial and was filed for review in late 2025. Orforglipron, a once-daily oral pill, is expected to be submitted or decided in 2026. Both remained investigational.
Even with an oral pill already on the market, the GLP-1 pipeline keeps advancing on two fronts.
March coverage clarified where the two most-watched candidates stand.
CagriSema, Novo Nordisk fixed-dose combination of the amylin analogue cagrilintide and semaglutide, was submitted for FDA review in December 2025. In a phase 3 trial, participants lost about 20.4 percent of body weight on average at 68 weeks, compared with about 14.9 percent on semaglutide alone, 11.5 percent on cagrilintide alone, and 3 percent on placebo, an improvement over semaglutide alone, though it fell short of the company higher internal goal. Its co-formulation requires a dual-chambered delivery device.
Orforglipron, Eli Lilly oral, small-molecule, non-peptide GLP-1, can be taken daily without the food and water restrictions of earlier oral options. Recent data indicated it helped people maintain weight loss after switching from injectable GLP-1s, and Lilly has signaled FDA submission with a possible decision in 2026. Both products remained investigational, in review or pre-submission, rather than available.
For consumers, more candidates mean more potential choice but also more complexity. CagriSema represents a push for deeper weight loss via a new mechanism; orforglipron represents convenience as a flexible daily pill. Neither is available yet, and average trial results describe studied populations, not individual outcomes. As always, suitability is a clinical decision, and headline percentages should be read as context, not promises.
Watch the FDA decision timelines and any manufacturing or supply considerations, CagriSema dual-chamber pen, for example, adds production complexity. Also watch whether orforglipron secures both weight-management and diabetes uses. For individuals, the practical posture is patience: filed or in trials is not available, timelines move, and any new approval will carry its own benefit-and-risk profile for specific groups rather than a universal recommendation.